Veracyte Has Released Our Inaugural ESG Report READ NOW
Search Tool Menu
Veracyte Has Released Our Inaugural ESG Report READ NOW
Close Button
Reducing Unnecessary Surgeries and Informing Treatment Decisions in cancer and other diseases
We continue to advance our portfolio of diagnostic tests to further improve patient care globally. Our new products leverage innovations in genomic science, sequencing technology and machine learning, among others.

Percepta Genomic Atlas (Lung Cancer) – This broad genomic profiling test is scheduled to launch in 2022 to help physicians make informed treatment decisions for patients diagnosed with lung cancer. Data presented at the American Thoracic Society (ATS) and American Society of Clinical Oncology (ASCO) meetings suggest that the test accurately detects known lung cancer gene variants using the same small biopsy samples that are used for diagnosis. This ability can simplify the physician’s workflow and accelerate time to appropriate treatment. The Percepta Genomic Atlas will be part of our comprehensive lung cancer portfolio, helping to guide care across the patient journey.

Genomic Tests on nCounter Analysis System – Our exclusive global access to the nCounter Analysis System for diagnostic testing positions us to make our genomic classifiers – currently performed in our centralized labs for patients in the U.S. – available to physicians and their patients globally. We plan to adapt our Percepta Nasal Swab (lung cancer), Decipher Prostate (prostate cancer) and Envisia (interstitial lung disease) genomic tests to the nCounter Analysis System.

LymphMark (Lymphoma) – We are developing this lymphoma subtyping test as a companion diagnostic for Acerta Pharma and AstraZeneca’s acalabrutinib (Calquence®). In April 2021, we announced that the first patient has been enrolled and randomized in Acerta Pharma’s Phase 3 ESCALADE trial, which uses the investigational LymphMark test to identify patients with untreated diffuse large B-cell lymphoma (DLBCL) who may benefit from Calquence in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy.